Legislative movement for menopause rights gains momentum in the US
Across America, lawmakers are passing new laws aimed at expanding access to menopause symptom treatment, educating healthcare providers, and ensuring insurance coverage for hormonal and non-hormonal therapies.
The gist: what's really happening
On the surface, the press portrays this as a series of scattered legislative initiatives on menopause. In reality, we are witnessing the formation of a new legal infrastructure that transforms perimenopause and menopause from a private medical issue into a protected social category with concrete financial implications for insurers, employers, and the femtech industry.
The process is unfolding along three tracks simultaneously: access to therapy, workplace protections, and research funding. This synchronicity is no coincidence—it is backed by years of work by lobbying groups that methodically prepared the legislative groundwork in individual states in 2024–2025, aiming to trigger a domino effect in 2026.
The user query points to "new laws across America" in the present tense. May 2026 has indeed become a tipping point: California is advancing AB432 (mandatory insurance coverage for menopause therapy), New Jersey is expanding the list of covered hormonal drugs to include testosterone, and federal authorities are preparing mandatory menopause action plans for employers with 250+ employees. But the media misses the systemic nature of what's happening. These are not just laws—they are the architecture of a market worth nearly $19 billion.
Timeline and context: from the first state to a national standard
The starting point was 2025, when Rhode Island became the first US state to include menopause in its anti-discrimination law, requiring employers to provide reasonable accommodations similar to those for pregnancy. This was a legal precedent that gave other states a ready-made template to copy.
Then events accelerated:
- February 2026: Illinois introduces a bill for 40 hours of paid menstrual leave plus a hybrid work format—and this is specifically about menopause, not just the cycle.
- March 2026: The UK publishes guidance on menopause action plans for employers—advisory from April 2026, mandatory from spring 2027. British experience is being actively monitored by US lawmakers.
- April 2026: The California Assembly Committee unanimously (7–0) passes AB432—a bill on insurance coverage for menopause therapy and physician training. New York, Virginia, and several other states are advancing similar bills. Congresswoman Emilia Sykes sends a request to Congress for $5 million for the Menopause Research to Action Network.
- May 2026: New Jersey introduces amendments S4054, directly including testosterone therapy in menopause coverage, with an important caveat: insurers cannot deny coverage even if the FDA has not approved the drug specifically for menopause.
A parallel track is the femtech market: according to Mordor Intelligence, it will reach $18.98 billion by 2031, with a CAGR of 14.2%. Legislative recognition of menopause as a distinct medical and employment category opens the floodgates for venture capital investment in this niche.
Who wins and who loses
Winners:
Femtech startups and their investors. Clear insurance coverage for menopause therapy means a guaranteed patient flow and reimbursement. I expect that in the second half of 2026, deal volume in the menopause tech segment will grow by at least 30% compared to the same period in 2025.
Law firms specializing in labor law. A new category of discrimination claims means years of litigation as courts define the boundaries of "reasonable accommodations" for menopause.
Fortune 500 employers that have already implemented menopause-friendly policies (flexible schedules, temperature control, additional breaks). They gain a competitive advantage in a labor market where 25–30% of female employees are of perimenopausal or menopausal age.
Losers:
Insurance companies. Each new coverage mandate increases actuarial costs. Particularly painful is the New Jersey amendment on testosterone: off-label use is virtually unrestricted, and insurers will be forced to pay for drugs without completed clinical trials for this indication.
Small businesses (50–249 employees). They are currently outside the scope of mandates, but British experience shows that regulators "recommend" compliance even for small companies. This means costs for HR restructuring without government support.
Medical schools and residency programs. Only 31% of obstetrics and gynecology programs include menopause in their curriculum. Now they will be forced to revise programs, and there is a shortage of instructors.
What the media leaves out
The main non-obvious fact: the legislative movement for menopause is inextricably linked to lobbying by manufacturers of bioidentical hormone therapy. The bioidentical hormone industry, already exceeding $3 billion in the US, has spent years pushing for its products to be included in insurance coverage. The S4054 amendment in New Jersey, which explicitly mentions "bioidentical hormone treatments," is the result of specific lobbying groups, not abstract concern for women's health.
Second point: menopause action plans in the UK are not just about health. They are a tool to retain women in the economy. According to UK government data, menopause pushes tens of thousands of skilled female workers out of the workforce each year. Mandating action plans for employers is essentially shifting the costs of the demographic crisis and labor shortage onto businesses.
Third point: the defeated bill in Colorado shows the real picture of resistance. Lawmakers fear that mandates will lead to higher insurance premiums for all insured individuals, making this a toxic issue in an election year. Behind every passed law is a defeated or stalled bill in another state.
Forecast: next 30 and 90 days
30 days (by June 20, 2026):
AB432 in California will pass the Privacy Committee and be sent for a vote in the Assembly. Given the 7–0 vote in the previous committee, passage is virtually guaranteed. This will be the biggest victory for pro-menopause legislation in 2026 and will trigger a wave of copying: at least three states (Washington, Oregon, Massachusetts) will accelerate their own bills.
Mordor Intelligence will release an updated forecast for the femtech market, raising estimates for the menopause management segment amid legislative changes. Shares of public companies in this niche will rise by 8–12%.
90 days (by August 20, 2026):
At the federal level, the Menopause Research to Action Network pilot will launch under the NIH—$5 million in funding is already included in budget discussions for FY2027. The first grants will be distributed by the end of the calendar year.
Large employers (Amazon, Google, JPMorgan) will voluntarily introduce menopause action plans, not waiting for 2027 when mandates take effect. This will become a new standard for corporate DEI—diversity, equity & inclusion agenda expands to include age and hormonal aspects.
Insurance companies will quietly lobby for annual limits on menopause therapy—informal discussions in relevant congressional committees are already underway. I estimate the probability of this counter-movement succeeding at 30%, but the very fact of insurer resistance will become public.
And the main strategic forecast: by the end of 2026, at least 10 states will have some form of menopause protection legislation, and a federal bill amending the FLSA (Fair Labor Standards Act) will be introduced in Congress. The question is not whether this will happen, but how much venture capital will enter the niche before regulatory certainty reduces the margins of early investments.
— Editorial Team
